- Algernon Pharmaceuticals (AGN) has been issued a patent for the treatment of interstitial lung disease with Ifenprodil
- The invention claims treating interstitial lung disease, including idiopathic pulmonary fibrosis, with Ifenprodil
- The base claims of the patent will be valid through 2038
- Algernon is a drug re-purposing company that investigates safe, already approved drugs for new disease applications
- Algernon Pharmaceuticals Inc. (AGN) is up 19.05 per cent on the day, trading at C$5.00 per share at 2 pm ET
Algernon Pharmaceuticals (AGN) has been issued a patent for the treatment of interstitial lung disease with NP-120 (Ifenprodil).
The invention claims treating interstitial lung disease, including idiopathic pulmonary fibrosis, with Ifenprodil. The base claims of the patent will be valid through 2038, excluding any patent term adjustments or extensions which may provide additional protection.
The company also has active patent applications for Ifenprodil for the same compositions and methods in the U.S., Europe, China and Japan.
Algernon’s intellectual property strategy for its repurposed drug program includes protecting its compounds by filing patent applications covering method of use for new disease indications, as well as dosing and formulation. In addition, the Company has filed new composition of matter patents for novel salt forms for some of its lead compounds.
Christopher J. Moreau, CEO of Algernon Pharmaceuticals, commented on the news.
“We are very pleased to be granted this patent by the CIPO. This is an important milestone for the company as we continue to strengthen our global IP position.”
Algernon is a drug re-purposing company that investigates safe, already approved drugs for new disease applications.
Algernon Pharmaceuticals Inc. (AGN) is up 19.05 per cent on the day, trading at C$5.00 per share at 2 pm ET.
